Hep C therapy may interact with amiodarone

The FDA is warning cardiologists that patients can develop life-threatening symptomatic bradycardia when the hepatitis C drugs ledipasvir/sofosbuvir or sofosbuvir combined with another direct-acting antiviral are taken together with amiodarone.

A review of postmarketing adverse event reports found that one patient on that regimen died from cardiac arrest and three others required placement of a pacemaker. The FDA could not determine the cause, but other patients recovered after discontinuing either the hepatitis C drug, amiodarone or both.

The FDA recommends physicians discontinue prescribing ledipasvir/sofosbuvir (Harvoni) or sofosbuvir (Sovaldi) combined with another direct-acting antiviral drug with amiodarone. In cases where alternative treatment options aren’t available, the FDA advised heart monitoring in an in-patient hospital setting for the first 48 hours followed by monitoring in a doctor’s office or self-monitoring every day through at least the first two weeks of treatment.

The FDA is continuing to investigate.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.